التفاصيل البيبلوغرافية
| العنوان: |
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab. |
| المؤلفون: |
Shah, Neil J.1 (AUTHOR) ShahN6@mskcc.org, Sura, Sneha D.2 (AUTHOR), Shinde, Reshma3 (AUTHOR), Shi, Junxin2 (AUTHOR), Singhal, Puneet3 (AUTHOR), Perini, Rodolfo F.3 (AUTHOR), Motzer, Robert J.1 (AUTHOR) |
| المصدر: |
Urologic Oncology. Nov2023, Vol. 41 Issue 11, p459.e1-459.e8. 1p. |
| مصطلحات موضوعية: |
*RENAL cell carcinoma, *TREATMENT effectiveness, *PROPORTIONAL hazards models, *DISEASE risk factors, *ELECTRONIC health records |
| مستخلص: |
• Immune-oncology treatments have changed treatment paradigm for front-line treatment of metastatic renal cell carcinoma. • Results for clinical outcomes for pembrolizumab+axitinib and ipilimumab+nivolumab from this real-world evidence study are along the lines of respective clinical trials. • Overall, our study provides additional evidence of these newer IO and TKI-based treatments among a more generalizable patient population from the US community settings. Immune-Oncology (IO) therapies have changed first-line (1L) treatment paradigm for metastatic renal cell carcinoma (mRCC) in last few years with robust clinical trial data. We examined clinical outcomes among clear cell mRCC (mccRCC) patients who received pembrolizumab + axitinib (pembro-axi) or ipilimumab + nivolumab (ipi-nivo) in the US community oncology setting. This retrospective cohort study utilized data from electronic health records and chart review within The US Oncology Network to identify adult patients with mccRCC initiating 1L pembro-axi or ipi-nivo from January 01, 2019 to December 31, 2020 and followed through March 31, 2021. Physician-recorded response (real-world overall response rate [rwORR] and real-world disease control rate [rwDCR]) was assessed descriptively. Real-world progression-free survival (rwPFS), real-world time to next treatment (rwTTNT) and time on treatment (rwToT) were estimated using Kaplan-Meier analysis. Association of 1L systemic treatment with time-to-event outcomes was examined using multivariable cox proportional hazards models. Study included 331 mccRCC patients (pembro-axi:44%, ipi-nivo:56%). Median age was 65 years, 75.5% were male, and 82.5% had intermediate/poor (I/P) IMDC risk score. RwORR and rwDCR were 71.0% and 80.0% for pembro-axi and 45.2% and 58.6% for ipi-nivo. In multivariable analysis, pembro-axi was associated with longer rwToT (aHR, 0.53 [95% CI, 0.40, 0.71]), rwTTNT (aHR, 0.60 [95% CI, 0.42, 0.87]), and rwPFS (aHR, 0.70 [95% CI, 0.49, 0.99]) compared to ipi-nivo (P < 0.01). Our study provides insight into newer mccRCC treatment tolerability and effectiveness in the real-world US community setting. Our real-world results were comparable to data from clinical trials, which is encouraging for mccRCC patients. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
